Course Overview

Print

SAVE THE DATE

This course will be held again on
October 8-9, 2020.

Information contained in this site is for the 2018 program.
Information for the 2020 program not yet available.

 

Thrombosis and Thromboembolism 2018
The State of the Art for Prevention, Evaluation and Treatment

This special course provides a comprehensive review of the most important changes and advances impacting the care of patients who have—or are at risk for—thrombosis and thromboembolism. Updates in diagnosis, treatment and prevention are provided by world-renowned experts and Harvard Medical School’s leading clinical faculty. The curriculum includes:

  • New options for testing and diagnosis of thrombotic disorders
  • Important developments in epidemiology and pathophysiology
  • Best practices for stroke prevention (and prediction) in atrial fibrillation
  • Guidance to navigate the nuances of prescribing dual antiplatelet therapy
  • When and how to use new oral anticoagulants and interventional devices
  • Personalized medicine and lipid biology
  • Updated lipid guidelines (and controversies surrounding them)
  • Expert advice to incorporate the latest science into your practice

This program has provided practical and timely education about innovations in this field since 1987. First-time and returning attendees consistently report that the knowledge they acquire from this update changes their practice and drives better outcomes for patients.

Participants will learn state-of-the-art approaches to preventing VTE in medically ill patients; how dual anti-platelet therapy can prevent MI, stroke, and leg amputation; improved stroke prediction and prevention; and a better understanding of the link between inflammation and thrombotic illnesses.

Attendees stay current with the state of the art for:

  • DVT/PE diagnosis and testing
  • Parenteral and oral anticoagulants
  • Atherothrombosis: etiology, pathophysiology, therapy
  • Anti-inflammatory therapy to reduce risk of cardiovascular events
  • Hypercoagulability: testing and management
  • Pharmacomechanical catheter-directed therapy
  • New approaches to treat high LDL cholesterol and hypertriglyceridemia
  • Dual antiplatelet therapy: dose, duration, reversibility
  • Stroke prevention in atrial fibrillation
  • Special considerations for VTE in cancer and pregnancy

This program is among the highest-rated Harvard Medical School CME courses.

Please note that this course is only offered once every two years, and seating is limited. To ensure a spot, early registration is strongly recommended.

Special Keynote Speakers

Eugene Braunwald, MD
Distinguished Hersey Professor of Medicine at Harvard Medical School
Founding Chairman of the TIMI Study Group at Brigham and Women’s Hospital

For more than 30 years, Dr. Braunwald has served as Chairman of the TIMI Study Group. Science Watch listed Dr. Braunwald as the most frequently cited author in cardiology; the living Nobel Prize winners in medicine voted Dr. Braunwald “the person who has contributed the most to cardiology in recent years.”

 

Calum A. MacRae, MD, PhD
Associate Professor of Medicine, Harvard Medical School
Vice Chair of Innovation, Brigham and Women’s Hospital

The recipient of the American Heart Association’s $75 million One Brave Idea award to understand the earliest stages of coronary heart disease, Dr. MacRae is also also the Vice Chair of Innovation at the Brigham and Women’s Hospital. In addition, Dr. MacRae is a leading investigator at the Brigham and Women’s Hospital Genomics Center, a principal faculty member at the Cardiovascular Research Center and the Harvard Stem Cell Institute, and an associate member at the Broad Institute.